跳至主要内容
临床试验/NCT06037941
NCT06037941招募中不适用

Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates

Memorial Sloan Kettering Cancer Center14 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年9月8日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
20
试验地点
14
主要终点
Change of MPMspecific VOCs

研究概览

简要总结

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
30 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 30-85 years
  • No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)
  • Recent diagnosis of MPM
  • Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection

排除标准

  • Aged <30 or >85 years at the first outpatient visit
  • History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases

结局指标

主要结局

Change of MPMspecific VOCs

时间窗: up to 1 year

compared with imaging (using RECIST 1.1 and mRECIST).

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验